+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Phenotypic profiling of third-generation cephalosporins Impact on screening for putative extended-spectrum beta-lactamases in E coli and K pneumoniae



Phenotypic profiling of third-generation cephalosporins Impact on screening for putative extended-spectrum beta-lactamases in E coli and K pneumoniae



Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 41: 155



Background: Laboratory screening of E. coli (EC), K. pneumoniae (KP), and other Enterobacteriaceae for putative extended-spectrum beta-lactamases (pESBLs) is important to guide treatment and implement infection control measures. Of the commonly tested third-generation cephalosporins (3GCs), ceftazidime (CTZ) is thought to be the most sensitive screen. To assess the current sensitivity of this screen, we determined the prevalence of pESBLs among CTZ-susceptible (S) isolates of EC and KP, as well as the impact that 3GC susceptibility has on multidrug-resistant (MDR) phenotypes involving agents of other classes. Methods: 1996-2001 susceptibility results from The Surveillance Network (TSN) Database-USA (>200 laboratories) were analyzed, which produced results for 140,268 EC and 41,464 KP concurrently tested against ceftriaxone (CTX), cefotaxime (CTM), CTZ, ciprofloxacin (CIP), gentamicin (GEN), and trimethoprim-sulfamethoxazole (SXT). Results: Overall S rates (%) for EC and KP were CTX (99.4, 95.7), CTM (99.1, 95.0), CTZ (98.5, 95.0), GEN (97.2, 93.8), CIP (96.8, 92.2), and SXT (82.1, 88.6). 98.2% of EC and 89.8% of KP were S to all 3GCs. Of the 2,517 EC that were nonsusceptible (NS; intermediate plus resistant (R)) to gtoreq1 3GCs, 84.2% were CTZ-NS, 54.2% were CTM-NS, and 53.2% were CTX-NS; 17.7% were R to all 3GCs. Of the 4,172 KP that were NS to gtoreq1 3GC, 93.2% were CTZ-NS, 68.2% were CTX-NS, and 62.5% were CTM-NS; 26.8% were R to all 3GCs. Of isolates that were S to all 3GCs or NS to >1 3GC, 1.0 and 23.4% of EC, and 0.4 and 21.4% KP, respectively, were R to GEN, CIP, and SXT (MDR). Conclusions: EC and KP that are S to CTZ and NS to CTX or CTM remain rare (15.8 and 6.8% of pESBL EC and KP; 0.3 and 0.7% of all EC and KP isolates). MDR, although predictably more common among isolates NS to gtoreq1 3GC, had similar rates of prevalence among EC (23.4%) and KP (21.4%).

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 035491992

Download citation: RISBibTeXText


Related references

Impact of third-generation cephalosporins restriction on the control of an extended-spectrum beta-lactamases producing Klebsiella pneumoniae outbreak in ICU. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 36: 222, 1996

Transfer of resistance to 3rd generation cephalosporins and aztreonam in strains of Klebsiella pneumoniae producing extended spectrum beta-lactamases. Epidemiologie Mikrobiologie Imunologie 48(1): 21-27, 1999

Transferable resistance to 3rd generation cephalosporins and aztreonam in strains of Klebsiella pneumoniae producing beta-lactamases with an extended spectrum (ESBL). Epidemiologie Mikrobiologie Imunologie 48(1): 21-27, 1999

Replacement of third-generation cephalosporins by piperacillin-tazobactam decreases colonization of extended-spectrum beta-lactamases-producing intestinal Escherichia coli. Zhonghua Nei Ke Za Zhi 46(9): 714-717, 2007

Phenotypic detection and occurrence of extended-spectrum beta-lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli at a tertiary hospital in Trinidad & Tobago. Brazilian Journal of Infectious Diseases 12(6): 516-520, 2008

Molecular characteristics of extended spectrum beta-lactamases in Escherichia coli and Klebsiella pneumoniae and the prevalence of qnr in Extended spectrum beta-lactamase isolates in a tertiary care hospital in Korea. Yonsei Medical Journal 51(5): 768-774, 2010

Finding the optimum agent to use for screening and confirmatory test for extended-spectrum beta-lactamases in E coli and K pneumoniae in Ramathibodi Hospital, Thailand. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 43: 167, 2003

Phenotypic Characterization of Multidrug-resistant Escherichia Coli with Special Reference to Extended-spectrum-beta-lactamases and Metallo-beta-lactamases in a Tertiary Care Center. Jnma; Journal of the Nepal Medical Association 53(198): 89-95, 2016

Phenotypic characteristics of clinical isolates of Klebsiella pneumoniae & evaluation of available phenotypic techniques for detection of extended spectrum beta-lactamases. Indian Journal of Medical Research 122(4): 330-337, 2005

Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases. Antimicrobial Agents and ChemoTherapy 55(5): 2434-2437, 2011

Interactions of meropenem, with beta-lactamases, including enzymes with extended-spectrum activity against third-generation cephalosporins. Journal of Antimicrobial ChemoTherapy 24 Suppl A: 219-223, 1989

In vitro activity of fourth generation cephalosporins against enterobacteriaceae producing extended-spectrum beta-lactamases. Journal of ChemoTherapy 8(Suppl. 2): 57-62, 1996

Screening and confirmatory testing for extended spectrum beta-lactamases in E coli, Klebsiella pneumoniae and Klebsiella oxytoca clinical isolates. Abstracts of the General Meeting of the American Society for Microbiology 99: 155-156, 1999

Detection of phenotype and genotype for extended spectrum beta-lactamases and AmpC beta-lactamases in Klebsiella pneumoniae, Klebsiella oxytoca and Escherichia coli. Abstracts of the General Meeting of the American Society for 106): 8, 2006

Screening and confirmatory testing for extended spectrum beta-lactamases (ESBL) in Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxytoca clinical isolates. Diagnostic Microbiology and Infectious Disease 36(2): 113-117, 2000